SCI-PUB

Non-Hodgkin's Lymphomas

Corrigendum to: Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.

No abstract text is available for this article

Neuro-oncology, 2023-02-08

Personalized approaches for treatment-naïve mantle cell lymphoma.

Given the wide array of disease and patient presentations with MCL, a personalized therapeutic approach is needed to optimize outcomes. The optimal therapeutic strategy should incorporate disease prognostic factors, patient status and comorbidities, goals of care, and response to treatment.

DOI: 10.1080/17474086.2023.2174516

Qualls D, Kumar A

Expert review of hematology, 2023-02-08

NEW

Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1-2 follicular lymphoma: a real-world multicenter study.

In conclusion, this study demonstrates a marked difference in clinical features and outcomes in FL3a patients compared with FL1-2 patients. The results highlight the need for applying therapeutic approaches distinct from FL1-2 when treating FL3a patients.

DOI: 10.1186/s40364-023-00462-z

Zha J, Chen Q, Ye J, Yu H, Yi S, Zheng Z, Xu W, Li Z, Ping L, He X, Zhang L, Li C, Xie Y, Chen F, Sun X, Su L, Zhang H, Fan L, Lin Z, Yang H, Zhao W, Qiu L, Li Z, Song Y, Xu B

Biomarker research, 2023-02-08

Ocular Involvement in a Patient with Intravascular Large B-Cell Lymphoma: A Diagnostic Challenge. Clinical Case Report and Literature Review.

Intravascular lymphoma is a rare form of extranodal diffuse large B-cell lymphoma, often with delayed diagnosis because of the nonspecific symptoms. Hence, random skin biopsy could be useful in the diagnosis.

DOI: 10.1080/09273948.2022.2103712

Sánchez-Vicente JL, De Las Morenas-Iglesias J, Franco-Ruedas C, Rueda-Rueda T, Moruno-Rodríguez A, Lechón-Caballero B, Romero-Martínez A, Del Estad-Caballero A, González-Jauregui B, Cabrera-Pérez R, López-Herrero F

Ocular immunology and inflammation, 2023-02-07

Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.

Low baseline NK-cell counts (NKCCs) in patients with diffuse large B-cell lymphoma (DLBCL) are associated with a poor prognosis...

DOI: 10.1111/bjh.18642

Beldi-Ferchiou A, Jais JP, Ghesquieres H, Casasnovas RO, Tilly H, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Perrot A, Nicolas-Virelizier E, Salles G, Godard N, Zamali I, De Colella JS, Claudel A, Corront B, Oberic L, Briere J, Gaulard P, Th

British journal of haematology, 2023-02-07

CD4/CD8 double-negative T-cell lymphoma successfully treated with a combination of bexarotene and total skin electron beam therapy.

No abstract text is available for this article

DOI: 10.1111/1346-8138.16739

Tanigawa A, Fukumoto T, Imamura S, Nakamura K, Tanaka T, Itoh T, Nakano E, Nishigori C, Kubo A

The Journal of dermatology, 2023-02-07

Primary extranodal soft tissue Lennert lymphoma (lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified): a case report and review of the literature.

Lennert lymphoma (LeL) is a rare variant of peripheral T-cell lymphoma, not otherwise specified (PTCL/NOS) that is rich in epithelioid histiocytes...

DOI: 10.1186/s13000-023-01297-w

Yin Y, Liu H, Luo M, Yu G, Yin W, Li P

Diagnostic pathology, 2023-02-05

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.

No abstract text is available for this article

DOI: 10.1182/blood.2022019294

Alderuccio JP, Reis IM, Koff JL, Larson MC, Chihara D, Zhao W, Haddadi S, Habermann TM, Martin P, Chapman J, Strouse CS, Kahl BS, Cohen JB, Friedberg JW, Cerhan JR, Flowers CR, Lossos IS

Blood, 2023-02-04

The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: A phase 2, single-arm, open-label clinical trial.

Linperlisib demonstrated compelling clinical activity and manageable tolerability for relapsed and/or refractory FL patients who had received at least two prior systemic therapies.

DOI: 10.1158/1078-0432.CCR-22-2939

Wang T, Sun X, Qiu L, Su H, Cao J, Li Z, Song Y, Zhang L, Li D, Wu H, Zhang W, Li J, Zhou KS, Zhou H, Yang Y, Li Z, Cen H, Cai Z, Zhang Z, Fu W, Jin J, Li F, Wu W, Gu X, Zhu W, Liu L, Li Z, Yi S, Bao H, Xu Z, Qiu L

Clinical cancer research : an official journal of the American Association for Cancer Research, 2023-02-04

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma.

Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)...

DOI: 10.1182/bloodadvances.2022009309

Shouse G, Kaempf A, Gordon MJ, Artz AS, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski SM, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV

Blood advances, 2023-02-04

Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma.

The aim of this study was to investigate the prognostic value of low T3 syndrome in follicular lymphoma (FL)...

DOI: 10.1007/s00277-023-05117-5

Xue LG, Shen HR, Gao R, Du KX, Xing TY, Wang WT, Wang L, Li JY, Liang JH, Xu W

Annals of hematology, 2023-02-04

Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the "RTL" (regional Tuscan lymphoma network).

Ibrutinib represents the first approved treatment for patients with Waldenström macroglobulinemia (WM)...

DOI: 10.1007/s00277-023-05113-9

Cencini E, Romano I, Ghio F, Camerini C, Bertaggia I, Giachetti R, Mannelli L, Pirrotta MT, Navei GL, Ciceri M, Cervetti G, Sant'Antonio E, Simonetti F, Birtolo S, Puccini B, Bocchia M, Fabbri A

Annals of hematology, 2023-02-04

MCL1 as a therapeutic vulnerability in Burkitt lymphoma.

No abstract text is available for this article

DOI: 10.1038/s41375-023-01827-x

Yuan R, Wang MY, Bi C, Zhao X, Tao J

Leukemia, 2023-02-04

Papillary Dermal Elastolysis Histopathology Mimicking Folliculotropic Mycosis Fungoides.

Papillary dermal elastolysis is a rare acquired disease of the elastic tissue that mainly affects elderly women with a clinical presentation of small firm papules in the neck, the supraclavicular areas and the upper back...

DOI: 10.1111/cup.14402

Recio Monescillo M, Torre-Castro J, Manzanas C, Ruffin B, Haya L, Rodríguez Pinilla M, Requena L

Journal of cutaneous pathology, 2023-02-04

Case of HIV presenting as retinal artery occlusion with further complications of Burkitt's lymphoma and CMV retinitis.

No abstract text is available for this article

DOI: 10.1136/bcr-2022-254096

Karande S, Khalsa A, Kelgaonkar A

BMJ case reports, 2023-02-07

Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma.

Given the infrequency of CTCL and its similar presentation to other common dermatologic conditions, increased education of CTCL is needed in the dermatology community to improve patient outcomes.

DOI: 10.1007/s13555-023-00895-2

Boh E, Kuraitis D, Jacobson A, Sikes M

Dermatology and therapy, 2023-02-03

A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

Preemptive TDF therapy in HBsAg-positive patients with diffuse large B-cell lymphoma receiving R-CHOP chemotherapy was safe and effective for preventing HBV-related hepatitis. However, a long-term maintenance strategy of preemptive TDF therapy should be recommended because of the relatively high rate of HBV-related hepatitis after withdrawal from TDF ( ClinicalTrials.gov ID: NCT02354846).

DOI: 10.14309/ajg.0000000000002185

Kim DY, Kim YR, Suh C, Yoon DH, Yang DH, Park Y, Eom HS, Lee JO, Kwak JY, Kang HJ, Hyun SY, Jo JC, Chang MH, Yoo KH, Lim SN, Shin HJ, Kim WS, Kim IH, Kim MK, Kim HJ, Lee WS, Mun YC, Kim JS

The American journal of gastroenterology, 2023-02-04

Role of 18F-fluorodeoxyglucose PET/computed tomography in the diagnosis and treatment response assessment of primary bone lymphoma.

PET/CT plays a substantial role in the diagnosis and treatment efficacy evaluation of PBL, and it should be recognized by clinicians and radiologists. Changes in metabolic parameters such as SUV, metabolic tumor volume and total lesion glycolysis have considerable potential for application in PBL diagnostics and treatment efficacy evaluation.

DOI: 10.1097/MNM.0000000000001668

Pu Y, Wang C, Xie R, Zhao S, Li K, Yang C, Li J, Xiang A, Wang Y, Chen L, Sun H

Nuclear medicine communications, 2023-02-03

Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities.

Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have shifted dramatically in the last 2 decades following the introduction of highly active immunotherapies such as rituximab...

DOI: 10.1182/blood.2021011994

Falchi L, Vardhana SA, Salles GA

Blood, 2023-02-03

Наверх

Non-Hodgkin's Lymphomas

Corrigendum to: Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.

Personalized approaches for treatment-naïve mantle cell lymphoma.

Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1-2 follicular lymphoma: a real-world multicenter study.

Ocular Involvement in a Patient with Intravascular Large B-Cell Lymphoma: A Diagnostic Challenge. Clinical Case Report and Literature Review.

Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.

CD4/CD8 double-negative T-cell lymphoma successfully treated with a combination of bexarotene and total skin electron beam therapy.

Primary extranodal soft tissue Lennert lymphoma (lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified): a case report and review of the literature.

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.

The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: A phase 2, single-arm, open-label clinical trial.

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma.

Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma.

Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the "RTL" (regional Tuscan lymphoma network).

MCL1 as a therapeutic vulnerability in Burkitt lymphoma.

Papillary Dermal Elastolysis Histopathology Mimicking Folliculotropic Mycosis Fungoides.

Case of HIV presenting as retinal artery occlusion with further complications of Burkitt's lymphoma and CMV retinitis.

Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma.

A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

Role of 18F-fluorodeoxyglucose PET/computed tomography in the diagnosis and treatment response assessment of primary bone lymphoma.

Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities.

Contact Us

Log In

Password recovery